Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway

Targeting the proteasome in combination with MDM2 inhibition activates the ATF4/CHOP stress response axis to induce apoptosis in liposarcoma, providing a potential therapeutic approach for the most common soft–tissue sarcoma.

[1]  P. Ambros,et al.  Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup , 2022, Scientific Reports.

[2]  Narasimhan P. Agaram,et al.  Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma , 2022, Nature Communications.

[3]  Narasimhan P. Agaram,et al.  Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets , 2021, Nature Communications.

[4]  R. A. Fan,et al.  Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism , 2021, International journal of molecular sciences.

[5]  D. Rizzotto,et al.  At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity , 2021, International journal of molecular sciences.

[6]  P. Venkatraman,et al.  PSMD9 ribosomal protein network maintains nucleolar architecture and WT p53 levels. , 2021, Biochemical and biophysical research communications.

[7]  O. Myklebost,et al.  Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening , 2021, PloS one.

[8]  J. Pearson,et al.  Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity , 2020, Nature Communications.

[9]  D. Mukhopadhyay,et al.  Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia , 2020, Leukemia & lymphoma.

[10]  W. Tilley,et al.  MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer , 2020, bioRxiv.

[11]  Dajun Yang,et al.  MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment , 2019, Journal of Immunotherapy for Cancer.

[12]  H. Atkins,et al.  Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. , 2019, Leukemia research.

[13]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[14]  J. Blay,et al.  Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma , 2019, Investigational New Drugs.

[15]  M. Bulyk,et al.  The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.

[16]  A. Maitra,et al.  p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. , 2019, Cancer cell.

[17]  A. Lin,et al.  Generating Single Cell–Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9 , 2019, Current protocols in molecular biology.

[18]  Robin L. Jones,et al.  Clinical and Molecular Spectrum of Liposarcoma , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Brian Bushnell,et al.  BBMerge – Accurate paired shotgun read merging via overlap , 2017, PloS one.

[20]  J. Espinosa,et al.  Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity , 2017, Genome research.

[21]  Dong Min Lee,et al.  Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis , 2017, Experimental &Molecular Medicine.

[22]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[23]  N. Curtin,et al.  Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer , 2017, Oncotarget.

[24]  R. Fåhraeus,et al.  p53-mediated suppression of BiP triggers BIK-induced apoptosis during prolonged endoplasmic reticulum stress , 2017, Cell Death and Differentiation.

[25]  Tero Aittokallio,et al.  SynergyFinder: a web application for analyzing drug combination dose–response matrix data , 2017, Bioinform..

[26]  Joon Sang Lee,et al.  TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma , 2016, Nature Communications.

[27]  Ahwan Pandey,et al.  Trisomy 21 consistently activates the interferon response , 2016, eLife.

[28]  M. Ri.  Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma , 2016, International Journal of Hematology.

[29]  A. Azab,et al.  Spotlight on ixazomib: potential in the treatment of multiple myeloma , 2016, Drug design, development and therapy.

[30]  F. Aversa,et al.  Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling , 2015, BioMed research international.

[31]  Sam W. Lee,et al.  Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway , 2015, Oncotarget.

[32]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[33]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[34]  Paul Theodor Pyl,et al.  HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[35]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[36]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[37]  Jing Zhang,et al.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.

[38]  Jean-Yves Blay,et al.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.

[39]  J. Schiffman,et al.  The Epidemiology of Sarcoma , 2012, Clinical Sarcoma Research.

[40]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[41]  Christopher C. Porter,et al.  ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53 , 2012, Nature chemical biology.

[42]  Q. Dou,et al.  Advances in the understanding of mechanisms and therapeutic use of bortezomib. , 2011, Discovery medicine.

[43]  Michael L. Wang.  Comparative mechanisms of action of proteasome inhibitors. , 2011, Oncology.

[44]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[45]  J. Kutok,et al.  Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. , 2011, Blood.

[46]  A. Lazar,et al.  An experimental model for the study of well differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors , 2010, Laboratory Investigation.

[47]  Serban Nacu,et al.  Fast and SNP-tolerant detection of complex variants and splicing in short reads , 2010, Bioinform..

[48]  L. Qin,et al.  Predicting Outcome by Growth Rate of Locally Recurrent Retroperitoneal Liposarcoma: The One Centimeter Per Month Rule , 2009, Annals of surgery.

[49]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[50]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[51]  M. Dai,et al.  Ribosomal Stress Couples the Unfolded Protein Response to p53-dependent Cell Cycle Arrest* , 2006, Journal of Biological Chemistry.

[52]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[53]  Robin L. Jones,et al.  Differential sensitivity of liposarcoma subtypes to chemotherapy. , 2005, European journal of cancer.

[54]  Lester F. Lau,et al.  Evidence of p53-Dependent Cross-Talk between Ribosome Biogenesis and the Cell Cycle: Effects of Nucleolar Protein Bop1 on G1/S Transition , 2001, Molecular and Cellular Biology.

[55]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[56]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .